The clinical relevance of the BAFF pathway in SLE has been established through the successful development of belimumab, a monoclonal antibody targeting soluble BAFF, which became the first approved biologic for SLE treatment (8). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.